Agents against common colds, SARS and other coronaviral diseases
Human coronaviruses (HcoV) are the major cause of diseases of the upper respiratory tract in humans. Apart from the common cold these include e.g. the life-threatening severe acute respiratory syndrome (SARS), that, originating in China, has appeared in other parts of the world with a mortality rate of 15%. A key enzyme for the replication cycle of the coronavirus is the HcoV proteinase Mpro. The functional relevance of Mpro makes it an attractive target for the development of drugs against SARS and other coronaviral diseases.
The present invention relates to a group of anticoronaviral agents whose functional mechanism is based on the specific blockade of the substrate binding site of HCoV Mpro. In vitro test systems have shown the substances according to the invention to be highly effective against several coronaviruses.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…